Relamorelin (RM-131) is a selective ghrelin receptor agonist; in a 12-week phase 2B study in 393 people with diabetic gastroparesis, vomiting frequency fell 75% from baseline, but not significantly more than on placebo.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Relamorelin (RM-131) is a selective ghrelin receptor agonist; in a 12-week phase 2B study in 393 people with diabetic gastroparesis, vomiting frequency fell 75% from baseline, but not significantly more than on placebo. · pmid:28760384
Mechanism
In 16 healthy volunteers, a single subcutaneous dose increased contractions of the distal stomach after a meal without changing gastric volumes, accommodation or satiation. · pmid:27283792
Proportion of the 2 claims about Relamorelin standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Relamorelin yet.
Dose evidence, rung by rung
No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
nothing resolved on this rung
Observational evidence· resolved human data at the emerging tier: thin, or contested
Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers. · pmid 27283792 · 2016
Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. · pmid 28760384 · 2017
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.